Meeting
2015 Gastrointestinal Cancers Symposium
DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas—Final results.
Authors
Thomas Jens Ettrich
Department of Internal Medicine I, University of Ulm, Ulm, Germany
Thomas Jens Ettrich , Lukas Perkhofer , Volker Kaechele , Andreas W. Berger , Melanie Guethle , Rainer Muche , Goetz von Wichert , Thomas M. Gress , Patrick Michl , Michael Geissler , Holger Frithjof Hebart , Petra Buechner-Steudel , Thomas Seufferlein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00690300
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 352)
DOI
10.1200/jco.2015.33.3_suppl.352
Abstract #
352
Poster Bd #
C21
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
DocOx (AIO-PK0106): A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas—Final results.
First Author: Thomas Jens Ettrich
Poster
2013 ASCO Annual Meeting
DOCOX: A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas.
First Author: Thomas Jens Ettrich
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nITRO: A phase 2 study of perioperative liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) in patients with resectable pancreatic ductal adenocarcinoma (rPDAC).
First Author: Davide Melisi
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
First Author: Esther Pijnappel